Heated humidified high-flow therapy

Getinge recieves US FDA 510(k) clearance for Servo-air® Lite

Retrieved on: 
Friday, July 7, 2023
Lite, Ventilation, Patient, Heated humidified high-flow therapy, CO2, Medical device, Getinge

GOTHENBURG, Sweden, July 7, 2023 /PRNewswire/ -- "We are happy to broaden our ventilator product offering for the US market", says Elin Frostehav, President Acute Care Therapies at Getinge. "This significantly increases our addressable ventilation market in the US, by now being able to target the non-invasive hospital segment with our ventilation offering." 

Key Points: 
  • Getinge announces clearance from the US FDA for Servo-air® Lite, a wall gas independent non-invasive mechanical ventilator.
  • GOTHENBURG, Sweden, July 7, 2023 /PRNewswire/ -- "We are happy to broaden our ventilator product offering for the US market", says Elin Frostehav, President Acute Care Therapies at Getinge.
  • "This significantly increases our addressable ventilation market in the US, by now being able to target the non-invasive hospital segment with our ventilation offering."
  • Servo-air® Lite is Getinge's turbine-driven ventilator for non-invasive ventilation.

Akumin Announces Appointment of New Directors

Retrieved on: 
Friday, December 16, 2022
IPO, UBS, PricewaterhouseCoopers, CT, PET, Bank of America, Diagnosis, MRI, Heated humidified high-flow therapy, Toronto, Patient, Bachelor of Commerce, CFO, Bank, Food and Drug Administration Amendments Act of 2007, Annual report, Hospital, Kushner Real Estate Group, Investment, Information, Monolithic kernel, Advisory board, Health, GAAP, University, Senior, Radiology, Risk, Commerce, Partner, TSX, Continuum, Moses Austin, Mammography, Security (finance)

Plantation, Fla., Dec. 16, 2022 /PRNewswire/ - Akumin Inc. (NASDAQ: AKU) (TSX: AKU) ("Akumin" or the "Company") is pleased to announce that John Wagner and Lawrence Ross Sinclair will join its board of directors effective January 1, 2023.

Key Points: 
  • Plantation, Fla., Dec. 16, 2022 /PRNewswire/ - Akumin Inc. (NASDAQ: AKU) (TSX: AKU) ("Akumin" or the "Company") is pleased to announce that John Wagner and Lawrence Ross Sinclair will join its board of directors effective January 1, 2023.
  • In addition to SCW Capital, Mr. Wagner is the co-founder and Managing Partner for Viewside Capital Partners.
  • Mr. Wagner is currently a member of the board of directors for D2 Solutions, Benefit Harbor, Strivant Health, and Flow Therapy.
  • These factors are not intended to represent a complete list of the factors that could affect Akumin; however, these factors should be considered carefully.

Flow Therapy Adds World-Renowned Cardiologist Timothy D. Henry to Board of Directors

Retrieved on: 
Wednesday, April 6, 2022
Blood, LinkedIn, The Christ Hospital, Heart, SCAI, Heated humidified high-flow therapy, Leadership, University of California, Irvine Medical Center, Society, Board, EECP, Cardiology, Health care, Research, Cedars-Sinai Medical Center, External counterpulsation, FACC, Medical director, Board of directors, Oxygen, Quality of life, University, Carl, Chest pain, GLOBE, Degenerative disease, Awareness, STEMI, Fatigue, Heart failure, Patient, Angina, Hospital, Medical imaging, Pharmaceutical industry

FORT WORTH, Texas, April 06, 2022 (GLOBE NEWSWIRE) -- World-renowned cardiologist Timothy D. Henry,MD, FACC, MSCAI, has joined Flow Therapy's Board of Directors.

Key Points: 
  • FORT WORTH, Texas, April 06, 2022 (GLOBE NEWSWIRE) -- World-renowned cardiologist Timothy D. Henry,MD, FACC, MSCAI, has joined Flow Therapy's Board of Directors.
  • The addition of Dr. Henry to its Board demonstrates Flow Therapy's continued commitment to quality and experience as the organization builds its value-focused treatment program.
  • Flow Therapy continues to make scientific contributions to show the effectiveness of our EECP program in refractory angina patients.
  • We are grateful that Dr. Henry will be advising Flow Therapy,"saysFlow Therapy President Michael Gratch.

During National Heart Health Month, Flow Therapy is Offering Free Heart Health Assessments

Retrieved on: 
Tuesday, February 8, 2022
Online, National Heart Valve Disease Awareness Day, Woman, Death, Doctor of Pharmacy, Heated humidified high-flow therapy, Twitter, Catalog, Quality of life, Heart, Program, Chest pain, FDA, Patient, American Heart Association, Oxygen, Cardiovascular disease, Life, Man, EECP, Walking, Degenerative disease, Instagram, Infarction, LinkedIn, 2009 Davis Cup, Fatigue, Blood, Gardening, Pharmaceutical industry, Medical imaging, Medical device, Goff–Gratch equation

FORT WORTH, Texas, Feb. 8, 2022 /PRNewswire-PRWeb/ -- February is National Heart Health Month, and with that in mind, Flow Therapy is helping to educate the public on symptoms that can indicate serious heart health problems, such as chest pain, fatigue and shortness of breath.

Key Points: 
  • FORT WORTH, Texas, Feb. 8, 2022 /PRNewswire-PRWeb/ -- February is National Heart Health Month, and with that in mind, Flow Therapy is helping to educate the public on symptoms that can indicate serious heart health problems, such as chest pain, fatigue and shortness of breath.
  • In conjunction, Flow Therapy is offering free, online assessments throughout the month to help catalog symptoms and identify those who can benefit from an Enhanced External Counter-pulsation (EECP) therapy program, an FDA-approved, non-invasive medical treatment for the management of significant symptoms of cardiovascular disease.
  • "Heart Health Month always brings my grandfather's story to mind and how we started," says Flow Therapy President and CEO Michael Gratch.
  • For more information, visit FlowTherapy.com or follow Flow Therapy on Facebook , LinkedIn , Instagram and Twitter .

Flow Therapy Opens Second Clinic in Greater San Antonio Area

Retrieved on: 
Monday, January 3, 2022
Twitter, Blood, Greater San Antonio, Health, Oxygen, EECP, Suite, Instagram, City, Time-invariant system, Quality of life, Physician, Degenerative disease, Heart, Chest pain, Program, Heated humidified high-flow therapy, Patient, Fatigue, Cardiology, LinkedIn, Medical imaging

Live Oak is Flow Therapy's eighth outpatient clinic nationwide, and it's second in the greater San Antonio area.

Key Points: 
  • Live Oak is Flow Therapy's eighth outpatient clinic nationwide, and it's second in the greater San Antonio area.
  • "We could not be more excited to open our second treatment center in the Greater San Antonio area, which will be located in Live Oak," said Flow Therapy CEO Michael Gratch.
  • "We're touched by how the San Antonio community has embraced our program and pleased with the clinical outcomes that Flow Therapy provides for patients.
  • Flow Therapy will host a ribbon-cutting ceremony at its new Live Oak clinic at 3 pm on Jan. 4.

Flow Therapy Studying the Effects of EECP® on Long COVID Symptoms

Retrieved on: 
Monday, December 13, 2021
COVID-19, Doctor of Pharmacy, Heated humidified high-flow therapy, Heart, FDA, Headache, Patient, MD, Fatigue, Oxygen, Physician, Diagnosis, Twitter, Cardiology, Time-invariant system, University of Texas Southwestern Medical Center, Common, Quality of life, Brain, EECP, COVID, Chest pain, LinkedIn, Heart failure, Degenerative disease, Instagram, Prevalence, Hope, Blood, Angina, Pharmaceutical industry, Medical imaging, Fort Worth, Texas

FORT WORTH, Texas, Dec. 13, 2021 /PRNewswire-PRWeb/ --Flow Therapy, the nation's leading provider of Enhanced External Counter-pulsation (EECP) services, a non-invasive treatment that increases blood flow to the heart and throughout the cardiovascular system, is studying the effects of EECP on long COVID symptoms.

Key Points: 
  • FORT WORTH, Texas, Dec. 13, 2021 /PRNewswire-PRWeb/ --Flow Therapy, the nation's leading provider of Enhanced External Counter-pulsation (EECP) services, a non-invasive treatment that increases blood flow to the heart and throughout the cardiovascular system, is studying the effects of EECP on long COVID symptoms.
  • "Long COVID hasn't been around that long, but long COVID symptoms like chest pain, shortness of breath and fatigue are also common to cardiology patients.
  • EECP has been used in medical settings to treat these symptoms in cardiology patients for years," says Sachin A. Shah, PharmD, chief scientific officer of Flow Therapy.
  • "EECP is not yet FDA-approved for long COVID treatment, but our initial results are promising.

Ventec Life Systems Receives Reimbursement Verification for V+Pro Ventilator

Retrieved on: 
Monday, September 20, 2021
PDAC, Ventilation, Ventec Life Systems, Data analysis, HCPCS, Heated humidified high-flow therapy, Multimedia, Patient, Health, Health care, Adult, Caregiver, Hospital, Durable medical equipment, COVID, PCL, HFT, COVID-19, Time, Heating, ventilation, and air conditioning

"Providing a family of products for patients and their caregivers is an essential element of Ventec Life System's operational objectives especially when ventilator demand is at the forefront due to the COVID-19 Delta variant," said Jim Alwan, President and Chief Executive Officer of Ventec Life Systems.

Key Points: 
  • "Providing a family of products for patients and their caregivers is an essential element of Ventec Life System's operational objectives especially when ventilator demand is at the forefront due to the COVID-19 Delta variant," said Jim Alwan, President and Chief Executive Officer of Ventec Life Systems.
  • "And with the addition of our V+Pro ventilator to our product portfolio, providers now have access to alternative respiratory products which they have not had before."
  • The V+Pro ventilator is coded and billed as E0465 or E0466, depending on how the device is being used.
  • Ventec Life Systemsis redefining respiratory care to improve patient outcomes and reduce caregiver challenges across all spectrums of patient care.

Global Nasal Cannula Market (2020 to 2027) - by Material, End-use, Type and Regional Outlook - ResearchAndMarkets.com

Retrieved on: 
Monday, July 26, 2021
Medical devices, Health, Medical equipment, Cannula, Nasal cannula, Heated humidified high-flow therapy

Nasal cannula finds potential applications in hospital settings, clinics, at home, or on the go.

Key Points: 
  • Nasal cannula finds potential applications in hospital settings, clinics, at home, or on the go.
  • Moreover, a nasal cannula is considered as a medical device that is a small and flexible tube.
  • The major market players are aiming at research & development activities and technological advancement to bring more flexible and comfortable nasal cannula in the market.
  • The market is facing a very high demand and thus, created various lucrative opportunities for the market players during the pandemic.

New ‘Negative Pressure Scavenger Kit’ Helps Hospitals Manage Infectious Particles When Treating Patients with COVID-19, Supports Non-Profits Supporting COVID-19 Front-Line Clinicians

Retrieved on: 
Wednesday, August 12, 2020
Nursing, Medical Supplies, Other Health, Health, Philanthropy, General Health, Other Philanthropy, Medical devices, Infectious diseases, Hospitals, Fund Raising, Medicine, Respiratory therapy, Medical specialties, Health care, Medical equipment, Mechanical ventilation, Intensive care medicine, Heated humidified high-flow therapy, Ventilator, Nasal cannula, Pulmonology, Permissive hypercapnia

All profits from the kits will be distributed to non-profit organizations supporting front-line clinicians fighting the COVID-19 pandemic.

Key Points: 
  • All profits from the kits will be distributed to non-profit organizations supporting front-line clinicians fighting the COVID-19 pandemic.
  • View the full release here: https://www.businesswire.com/news/home/20200812005383/en/
    Patient treated with Vapotherm high velocity therapy while using the FELIX-1 negative pressure scavenger kit (Photo: Business Wire)
    The FELIX-1 negative pressure scavenger kit is a preassembled tool compatible with high velocity therapy, an advanced form of high flow nasal cannula increasingly used by clinicians in supporting the respiratory needs of COVID-19 patients.
  • The company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders.
  • Vapotherm high velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distressincluding hypercapnia, hypoxemia, and dyspnea.

COVID-19 Pushes Sales of High Flow Nasal Cannula: Future Market Insights Study

Retrieved on: 
Wednesday, July 15, 2020
Medical equipment, Medicine, Respiratory therapy, Clinical medicine, Health care, Oxygen, Heated humidified high-flow therapy, Mechanical ventilation, Nasal cannula, Oxygen therapy, Cannula

DUBAI, U.A.E, July 15, 2020 /PRNewswire/ -- Market research company Future Market Insights' projections on the high flow nasal cannula market reveal that the market is slated to be valued at ~US$ 18 Bn by 2030.

Key Points: 
  • DUBAI, U.A.E, July 15, 2020 /PRNewswire/ -- Market research company Future Market Insights' projections on the high flow nasal cannula market reveal that the market is slated to be valued at ~US$ 18 Bn by 2030.
  • Growing prevalence of respiratory disorders have led to an increase in the uptake of high-flow nasal cannula (HFNC) devices.
  • The Center for Disease Control and Prevention (CDC) acknowledges the high-flow nasal cannula oxygenation therapy as a standard recommended therapy across the United States, especially during the COVID-19 pandemic.
  • For more insights into the Market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-11269
    Smooth oxygen delivery of heated, humidified oxygen at a flow rate of 60 liters per minute makes HFNC an ideal treatment method for respiratory patients
    High Flow Nasal Cannula Market: Region-wise Analysis
    Single-use HFNC devices are gaining traction across the German, Japanese and English markets respectively
    For information on the research approach used in the report, request methodology@ https://www.futuremarketinsights.com/askus/rep-gb-11269
    High Flow Nasal Cannula Market: Competitive Landscape
    The high flow nasal cannula market is characterized by the presence of numerous players, making the market highly fragmented.